p-Cresol sulfate (PCS)

p-Cresol sulfate (PCS) is a major protein-bound uremic toxin produced through the fermentation of tyrosine and phenylalanine by gut microbiota, such as Clostridioides difficile and Bacteroides species (Gryp et al., 2017, Toxins). Once p-cresol is generated in the colon, it is absorbed and conjugated with sulfate in the liver to form PCS, which is normally excreted by the kidneys through organic anion transporters OAT1 and OAT3 (Niwa, 2011, Journal of Renal Nutrition). In patients with chronic kidney disease (CKD), the impaired renal clearance leads to the systemic accumulation of PCS, which is highly bound to albumin (approximately 90%), making it difficult to remove via conventional hemodialysis (Meijers et al., 2008, Kidney International). Elevated levels of PCS are clinically significant as they are linked to the progression of CKD, cardiovascular disease, and increased mortality by promoting oxidative stress, vascular calcification, and systemic inflammation (Lin et al., 2015, Scientific Reports). Therapeutic strategies targeting PCS include the use of oral adsorbents like AST-120, which sequesters the precursor p-cresol in the gut, and the administration of prebiotics or probiotics to modulate the gut microbiome and reduce toxin production (Rossi et al., 2016, Journal of the American Society of Nephrology).

Other names

4-Methylphenyl sulfatep-Cresyl sulfate4-Cresyl sulfatep-Tolyl sulfate

Therapeutic strategies focus on the adsorption of the precursor p-cresol in the gastrointestinal tract to prevent systemic absorption and subsequent sulfation in the liver (Niwa, 2011, J. Ren. Nutr.), or the use of specialized dialysis and gut microbiome modulation to reduce toxin levels (Rossi et al., 2016, JASN).